Emerging roles of senolytics/senomorphics in HIV-related co-morbidities
Authors:
- 29 March 2024
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 228, 116179
Abstract
No abstract availableKeywords
Funding Information
- NIH (HL167655-A1, HL147715-01, AG075931, ES029177, R01 HL158316-A1)
This publication has 194 references indexed in Scilit:
- Exploring the fuzzy border between senolytics and senomorphics with chemoinformatics and systems pharmacologyBiogerontology, 2022
- Comorbidities in Persons With HIVJAMA, 2020
- Safety Aspects of the Use of Quercetin as a Dietary SupplementMolecular Nutrition & Food Research, 2017
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2015
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in miceHepatology, 2011
- Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart DiseaseArchives of internal medicine (1960), 2011
- Pulmonary HypertensionJAMA, 2008
- Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort StudyArchives of internal medicine (1960), 2005
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of internal medicine (1960), 2000